Copy to clipboard 
SINTX Technologies, specialist in silicon nitride (Si₃N₄) material for medical device applications, issued a multi-point business update to highlight progress from the company’s recent SiNAPTIC acquisition, strategic transformation and a revitalized commercialization strategy aimed at accelerating growth over the next 12 to 24 months.
Commercial Product Expansion and Acquisition of SiNAPTIC
SINTX continues to provide spinal interbody devices to CTL/Amedica. To date, over 50,000 devices have been successfully implanted. In July 2025, SINTX completed a significant acquisition of SiNAPTIC Surgical, a developer of silicon nitride implants. The current portfolio of differentiated orthopedic and spine technologies includes:
- FDA 510(k)-cleared interbody spinal implants made from a proprietary silicon nitride ceramic biomaterial
- Foot and ankle fusion wedges, for which a new 510(k) premarket notification was submitted in July 2025
Eric Olson, Chairman and CEO, stated, “These next-generation implants combine the osteoconductive, antimicrobial and imaging advantages of silicon nitride with the versatility of polymers already trusted by surgeons, all of which present significant opportunities for revenue and margin growth. The next six to twelve months will be even more transformative as we execute our strategic plans and redefine the medical device category.”
Expansion of Leadership Team
The acquisition of SiNAPTIC also brought a team of leaders to SINTX:
- Bryan Scheer, M.D. – Orthopedic surgeon, MedTech entrepreneur, and founder of SiNAPTIC, now Chairman of the Clinical Advisory Board of SINTX
- Hugh Roberts – Co-founder of SiNAPTIC and industry veteran with a track record in product innovation and commercialization, now Managing Director of Business Development
- Lisa Marie Del Re – experienced in launching and scaling orthopedic sales channels, now Chief Commercial Officer
- Brian Hockett – expert in surgical R&D and engineering, now serving as Senior Vice President of Regulatory and Quality Affairs
Streamlined Operations and Strategic Focus on Medical Devices
Over the past year, SINTX has executed a restructuring effort aimed at focusing exclusively on high-margin, high-growth opportunities in orthopedic and surgical markets. Key actions include:
- Divestiture of Non-Core Assets: In February 2025, SINTX sold its Maryland-based subsidiary, Technology Assessment & Transfer, Inc.
- Termination of Non-Strategic Operations: In August 2024, SINTX shut down its armor ceramics facility
- Exit from Low-Margin OEM Manufacturing: The company’s slight decrease in revenue during Q2 2025 reflects a purposeful transition away from technical ceramics contracts that did not align with long-term profitability goals
Future Growth Strategy
Looking ahead, SINTX will continue to build on its scientific foundation and IP portfolio. Recent advancements include:
- The company has filed multiple new patents related to composite implant design, additive manufacturing and antimicrobial ceramics.
- Peer-reviewed publications validating the performance of silicon nitride in orthopedic and surgical applications, including 3D-printed implant composites with properties that match cortical bone.
“SINTX is now positioned to lead the next wave of innovation in medical technology,” said Eric Olson. “In just six months, we have rebuilt the Company from the ground up—bringing in world-class leadership, streamlining operations, divesting non-core assets, and executing a focused commercialization strategy designed to deliver breakthrough medical solutions and create substantial shareholder value. We are one of the only companies worldwide with both the intellectual property and manufacturing expertise to deliver advanced silicon nitride biomaterials in multiple formats to the medical device industry.”
Source: SINTX Technologies, Inc.
